Imperia Ephedra
Natural health product licensed in Canada
- Licence holder
- Imperia Brand Strategies & Solutions Ltd.
- NPN or DIN-HM
- 80045141
- Status
- Active licence
- Licence date
- 1 October 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Cellulose microcristalline, Eau, Stéarate de magnésium, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | minimum: 1 day ; maximum: 4 days |
Uses authorised in Canada
Used in Herbal Medicine as a decongestant/ to relieve nasal congestion. Used in Herbal Medicine as a decongestant/ to relieve nasal congestion (due to flu). Used in Herbal Medicine as a decongestant/ to relieve nasal congestion (due to hay fever/allergic rhinitis/allergies). Used in Herbal Medicine as a decongestant/ to relieve nasal congestion (due to sinusitis). Used in Herbal Medicine as a decongestant/ to relieve nasal congestion (due to the common cold).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Shortness of breath, and/or disturbance of urination have been known to occur; in which case, discontinue use. Severe headache has been known to occur; in which case, discontinue use. Restlessness has been known to occur; in which case, discontinue use. Rapid heartbeat has been known to occur; in which case, discontinue use. Nausea and/or loss of appetite have been known to occur; in which case, discontinue use. Irritability, dizziness and/or tremor have been known to occur; in which case, discontinue use. Insomnia has been known to occur; in which case, discontinue use.
- Précautions et mises en garde
Keep out of reach of children. Consult a health care practitioner prior to use if you have thyroid problems. Consult a health care practitioner prior to use if you have seizure disorders. Consult a health care practitioner prior to use if you have pre-existing psychiatric conditions. Consult a health care practitioner prior to use if you have glaucoma. Consult a health care practitioner prior to use if you have difficulty in urination due to prostate enlargement. Consult a health care practitioner prior to use if you have diabetes. Consult a health care practitioner prior to use if you have cardiovascular disease. Consult a healthcare practitioner prior to use if you are taking other products which contain pseudoephedrine. Consult a healthcare practitioner prior to use if you are taking other products which contain phenylpropanolamine. Consult a healthcare practitioner prior to use if you are taking other products which contain ephedrine. Consult a healthcare practitioner prior to use if you are taking other products which contain caffeine. Consult a health care practitioner prior to use if you are taking medication and/or natural health products for weight control. Consult a health care practitioner prior to use if you are taking medication and/or natural health products for cough/cold. Consult a health care practitioner prior to use if you are taking medication and/or natural health products for asthma. Consult a health care practitioner prior to use if you are taking medication and/or natural health products for allergy symptoms. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner if symptoms persist.
- Contre-indications
Do not use if you are taking, or have taken in the past two weeks monoamine oxidase (MAO) inhibitors.
Source
Official Health Canada record, licence 80045141
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.